Pfizer Shares Surge Nearly Four Per Cent on Vaccine Report

Further, Pfizer and BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints.

from Top Business News- News18.com https://ift.tt/32WFEz9